Table 2.

Results of complement analyses after eculizumab (3 × 600 mg within 6 d)a

DayAPH50 (%)C3 (mg/ml)C3d (mU/L)SC5b-9 (ng/ml)
3<51.04401524
6nt0.93351450
9<50.80431348
12nt0.77451093
14nt0.73451774
16<50.87372149
19nt0.78171930
23390.74551676
26nt0.69441894
30470.70462207
35nt0.87441772
371240.82481809
40nt0.90521896
44nt0.80441064
471340.69381365
  • a nt, not tested.